Clinical Trials Directory

Trials / Completed

CompletedNCT00550485

Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene

Blood-brain-barrier Permeability of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene: Effect on Sleep and Procedural Learning

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
79 (actual)
Sponsor
Max-Planck-Institute of Psychiatry · Academic / Other
Sex
Male
Age
20 Years – 30 Years
Healthy volunteers
Accepted

Summary

The ABCB1-gene product P-glycoprotein is an integral membrane protein that actively transports substrates out of the intracellular compartment. One of the major sites of its action is the blood-brain-barrier. It is highly expressed in brain capillary endothelial cells and involved in limiting the access of substrates such as antidepressants to the central nervous system. A single nucleotide polymorphism (SNP) of the ABCB1-gene was recently identified showing a different treatment response to antidepressant drugs depending on the genotype. Therefore, it is assumed that healthy subjects with different genotypes of that SNP will be associated with significantly different brain levels of the antidepressant escitalopram after 6 days of intake. Sleep recordings are a useful bio-marker for effects of antidepressants on the CNS. Selective serotonin reuptake inhibitors (e.g. escitalopram) cause a suppression of REM sleep and a stronger fragmentation of sleep compared to untreated subjects. Higher plasma levels of antidepressants affected the sleep to a greater extent than lower levels. In line with this finding, we suppose that sleep EEG recordings of healthy subjects with different genotypes of the above mentioned SNP will be differently affected after taking 6 days escitalopram. In addition, effects of drug intake on the gene expression in lymphocytes and metabolic changes will be assessed.

Conditions

Interventions

TypeNameDescription
DRUGescitalopramescitalopram 4 mg

Timeline

Start date
2007-10-01
Primary completion
2018-07-06
Completion
2018-07-06
First posted
2007-10-30
Last updated
2019-03-27

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00550485. Inclusion in this directory is not an endorsement.

Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene (NCT00550485) · Clinical Trials Directory